3,>=4 prior line of therapy, Phase 2, Teclistamab, B-Cell Maturation Antigens (BCMA) Bispecific Antibody, Relapsed Refractory Multiple Myeloma (RRMM)
### Instruction:
Identify the study with the following condition. 
### Input:
3,>=4 prior line of therapy, Phase 2, Teclistamab, B-Cell Maturation Antigens (BCMA) Bispecific Antibody, Relapsed Refractory Multiple Myeloma (RRMM) 
### Output:
Popular Name is MajesTEC-1, Study ID is NCT04557098